Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real-world study.

ABSTRACT:

Aims

Acquired hypothalamic obesity (aHO) following craniopharyngioma (CP) is a challenging condition with limited therapeutic options. This study aimed to assess the real-world effectiveness and safety of GLP-1 RAs in this population.

Materials and methods

CranioGLP1 is a retrospective multicentre study including 116 adults with aHO treated with one or more GLP-1 RAs across 16 French obesity centres. Demographic, clinical, and therapeutic data were collected from medical records. Weight outcomes, adverse events, and predictors of response were analysed.

Results

Patients had a mean age of 44.4 ± 13.5 years and a mean BMI of 40.1 ± 8.6 kg/m², 42% had type 2 diabetes. Over a mean follow-up of 44 months, mean weight loss was -4.6% (±12.5), with high interindivi

SUBMITTER: Lambert F 

PROVIDER: S-EPMC12673446 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature